The Technical Analyst
Teva Pharmaceutical [TEVA]
Exchange: NYSE Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
Teva Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals
12.83% $15.74
America/New_York / 8 mai 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 17 644 mill |
| EPS: | -0.500 |
| P/E: | -31.48 |
| Earnings Date: | May 08, 2024 |
| SharesOutstanding: | 1 120.99 mill |
| Avg Daily Volume: | 9.29 mill |
| RATING 2024-05-08 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -31.48 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.15x |
| Company: PE -31.48 | industry: PE 27.41 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-4.38 (-127.84%) $-20.12 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 15.38 - 16.10 ( +/- 2.31%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-05 | Kalif Eliyahu Sharon | Buy | 21 387 | Ordinary Shares |
| 2024-03-05 | Kalif Eliyahu Sharon | Buy | 52 320 | Ordinary Shares |
| 2024-03-06 | Kalif Eliyahu Sharon | Sell | 77 550 | Ordinary Shares |
| 2024-03-05 | Kalif Eliyahu Sharon | Sell | 21 387 | Restricted Share Units |
| 2024-03-05 | Kalif Eliyahu Sharon | Sell | 52 320 | Restricted Share Units |
| INSIDER POWER |
|---|
| 16.79 |
| Last 98 transactions |
| Buy: 2 305 980 | Sell: 1 612 593 |
Forecast:
16:00 - $15.74
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $15.74
Forecast 2: 16:00 - $15.74
Forecast 3: 16:00 - $15.74
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $15.74 (12.83% ) |
| Volume | 38.36 mill |
| Avg. Vol. | 9.29 mill |
| % of Avg. Vol | 413.03 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For TEVA
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
TEVA
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Last 10 Buy Signals
Latest Press Releases
2024-05-08 07:00:00 - Press Release
Teva Reports First Quarter 2024 Financial Results And Reaffirms 2024 Financial Outlook
Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) today reported results for the quarter ended march 31, 2024. mr. richard francis, teva's president and ceo, said, "in 2024 teva is off to a good start, with global revenues of $3.8 billion showing growth of 5% in local currency terms compared to q1 2023, fueled by robust growth in our generics business across all regions, and continued growth of our innovative brands austedo and ajovy." mr. francis cont.
2024-05-08 06:30:00 - Press Release
Teva And Medincell Announce Positive Phase 3 Efficacy Results From Solaris Trial Evaluating Tev-‘749 (olanzapine) As A Once-monthly Subcutaneous Long-acting Injectable In Adults With Schizophrenia
Parsippany, n.j. & tel aviv & paris--(business wire)--access here the complete press release teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), and medincell (euronext: medcl), today announced results from the efficacy portion of the phase 3 subcutaneous olanzapine extended-release injection study (solaris) trial evaluating tev-‘749 in adult patients with schizophrenia compared to placebo. results demonstrated that tev-‘749 met its primary endpo.
2024-05-02 18:30:00 - Press Release
Teva To Present At The 2024 Bank Of America Healthcare Conference
Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) today announced that richard francis, teva's president and ceo, will present at the 2024 bank of america healthcare conference on tuesday, may 14, 2024. the presentation will begin at 8:40 a.m. pacific time (11:40 a.m. eastern time). to access a live webcast of the presentation, visit teva's investor relations website at https://ir.tevapharm.com/events-and-presentations. an archived version of the webca.
2024-05-02 08:30:00 - Press Release
Teva's 2023 Healthy Future Report Showcases Renewed Sustainability Strategy And Ambitious Targets
Tel aviv, israel--(business wire)--teva pharmaceutical industries ltd. (nyse and tase: teva) today published its 2023 healthy future report, sharing its actions to promote healthy people, a healthy planet and a healthy business. the report unveils new targets to achieve net zero emissions across teva's operations and value chain by 2045 and 100% renewable electricity across all teva sites by 2035, as well as to reach 200% more total beneficiaries of health system strengthening and capacity buil.
2024-04-11 08:30:00 - Press Release
Teva Confirms Efficacy And Safety Of Ajovy® (fremanezumab) For The Prevention Of Migraine With Results From Phase 3 Trial In China
Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced results from a phase 3 study evaluating the efficacy and safety of ajovy for the prevention of migraine in adult chinese patients. in the study, ajovy achieved primary endpoint and all secondary endpoints, significantly reducing the number of migraine days experienced per month, demonstrating superior efficacy over placebo. al.
Latest News
2024-05-08 10:36:46 - Zacks Investment Research
Teva Pharmaceutical Industries (TEVA) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for Teva Pharmaceutical Industries (TEVA) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2024-05-08 09:15:00 - Market Watch
Teva Pharmaceutical's stock climbs as schizophrenia treatment shows promise
Teva Pharmaceutical Industries Ltd.'s American depositary receipts TEVA jumped more than 6% premarket Wednesday after the company reported first-quarter sales that topped expectations and released positive late-stage trial data on a schizophrenia treatment.
2024-05-08 07:20:26 - Reuters
Teva Pharm Q1 profit falls short of estimates, revenue gains
Teva Pharmaceutical Industries reported a smaller than expected rise in first-quarter profit citing higher impairments of tangible assets, while sales of copycat medicines and its branded drugs to treat migraines and Huntington's disease rose.
2024-05-08 06:41:19 - Reuters
Teva and Medincell's schizophrenia drug meets main goal of late-stage study
Teva Pharmaceuticals , and partner Medincell said on Wednesday their experimental schizophrenia drug had met its main goal in a late-stage study.
2024-05-06 11:41:03 - Zacks Investment Research
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
2024-05-03 10:21:32 - Zacks Investment Research
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key Metrics
Evaluate the expected performance of Teva Pharmaceutical Industries (TEVA) for the quarter ended March 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
2024-05-02 18:30:00 - Business Wire
Teva to Present at the 2024 Bank of America Healthcare Conference
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva's Investor Relations website at https://ir.tevapharm.com/Events-and-Presentations. An archived version of the webca.
2024-04-30 13:56:08 - Forbes
FTC Warns ‘Junk Patents' Could Make Drugs Like Ozempic Pricier—Here's How
The Federal Trade Commission is challenging hundreds of alleged “junk” patent listings filed by several pharmaceutical companies, which regulators claim could increase prices for medications like Novo Nordisk's diabetes drug Ozempic by making it harder to produce generic drugs.
2024-04-23 16:44:02 - InvestorPlace
You Would Fire “God” As Your Portfolio Manager
2024-04-18 12:16:10 - Zacks Investment Research
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
The impact of macroeconomic headwinds on the Zacks Medical - Generic Drugs industry is gradually improving. New product launches provide some respite to RDY, TEVA and VTRS.